Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Evaluation of Itgb2 (Cd18) and Sell (Cd62l) Genes Expression and Methylation of Itgb2 Promoter Region in Patients With Systemic Sclerosis Publisher Pubmed



Dashti N1, 2 ; Mahmoudi M1 ; Gharibdoost F1 ; Kavosi H1 ; Rezaei R1, 2 ; Imeni V1 ; Jamshidi A1 ; Aslani S1 ; Mostafaei S1 ; Vodjgani M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran

Source: Rheumatology International Published:2018


Abstract

Systemic sclerosis (SSc), an autoimmune disease of connective tissue, is characterized by inflammation, fibrosis, and vessel endothelial damage. Products of Integrin subunit beta 2 (ITGB2) and selectin L (SELL) genes participate in several functional pathways of immune system. The aim of this investigation was to survey the transcript level of ITGB2 and SELL genes as well as methylation status of CpG sites in promoter region of differently expressed gene in PBMCs of SSc patients. PBMCs were isolated from whole blood of 50 SSc patients and 30 healthy controls. Total RNA and DNA contents of PBMCs were extracted. Gene expression was analyzed by real-time PCR using the SYBR Green PCR Master Mix. To investigate the methylation status of CpG sites, DNA samples were treated by bisulfite, amplified through nested PCR, and sequenced through Sanger difficult sequencing method. ITGB2 gene in PBMCs of SSc patients was overexpressed significantly in comparison to healthy controls. However, no altered SELL expression was observed. Three CpG sites of 12, 13 and 14 were significantly hypomethylated in patients group, despite overall methylation status of ITGB2 gene promoter revealed no significant difference between study groups. There was no statistically significant correlation between methylation status of ITGB2 promoter and the gene expression in patients. Regarding to lack of correlation of increased expression of ITGB2 with its promoter hypomethylation in SSc patients, our study suggests that upregulation of ITGB2 in PBMCs from SSc patients is probably due to another mechanism other than methylation alteration. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
Other Related Docs
27. Autoimmune Diseases, Clinical Immunology (2022)
29. The Immunogenetics of Systemic Sclerosis, Advances in Experimental Medicine and Biology (2022)
38. Genetic Implications in the Pathogenesis of Systemic Sclerosis, International Journal of Rheumatic Diseases (2018)
41. Downregulation of Aquaporin3 in Systemic Sclerosis Dermal Fibroblasts, Iranian Journal of Allergy# Asthma and Immunology (2017)
49. Epigenetics of Autoimmune Diseases, Prognostic Epigenetics (2019)